REVIEW article
Front. Med.
Sec. Hepatobiliary Diseases
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1653452
Asialoglycoprotein Receptor 1: A Multifaceted Receptor in the Liver and Cardiovascular System
Provisionally accepted
- 1University of South China Hengyang Medical School, Hengyang, China
- 2Changsha Central Hospital, Changsha, China
- 3The Affiliated Changsha Central Hospital, Changsha Tuberculosis Research Institute, Hengyang Medical School, University of South China, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Sialic acid is a common terminal monosaccharide residue on glycan chains, and desialylation of glycoproteins is considered an important biological signal. In the liver and other cell types, asialoglycoprotein receptor 1 (ASGR1) specifically recognizes and binds to exposed galactose or N-acetylgalactosamine (Gal/GalNAc) residues on desialylated glycoproteins, and activates downstream signaling pathways through receptor-mediated endocytosis (RME), thereby playing important roles in various physiological and pathological processes such as immune regulation, viral infection, hepatocellular carcinoma progression, and lipid metabolism. In addition, ASGR1 is regarded as a key target for liver-specific drug delivery. This review systematically describes the molecular structure and physiological functions of ASGR1, its roles in pathological processes, and its potential functions in extrahepatic tissues. It provides essential background information for a comprehensive understanding of ASGR1 and offers novel insights into future research directions.
Keywords: ASGR1, glycoprotein recognition, viral infection, Lipid Metabolism, Hepatocellular Carcinoma, Targeted Drug Delivery
Received: 25 Jun 2025; Accepted: 24 Jul 2025.
Copyright: © 2025 Xiao, Nie and Leng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yiping Leng, The Affiliated Changsha Central Hospital, Changsha Tuberculosis Research Institute, Hengyang Medical School, University of South China, Changsha, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.